Breaking News

CPR Pharma Expands APAC Capabilities

March 26, 2013

Adds bioanalytical assay services

CPR Pharma Services has expanded it services in the Asia-Pacific region with a new lab in Adelaide, Australia that offers ligand binding assay services for biomarkers, monoclonal antibodies, biosimilars and biologics for early and late phase development. 
 
The new large molecule immunochemistry analytical service will be run by John Chappell, an expert in ligand binding assay development, validation and implementation. Mr. Chappell is a member of the AAPS Committee and has more than 20 years of CRO experience having held positions with Covance, ClinTrials BioResearch, BAS Analytics, Veeda and ICON. 
 
CPR’s chief executive officer, Jason Valentine, said, “John’s appointment with CPR will bring unparalleled expertise in biologic and biosimilar assay development and validation to the Asia/Pacific region. Monoclonal antibodies, proteins, biologics and biosimilars are the new growth areas in drug development and will progressively occupy a larger share of drugs developed globally. Couple this with the increased emphasis on biomarker monitoring in clinical trials and large molecule quantification is critical to any modern bioanalysis laboratory.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important